1. Home
  2. LPTX vs KLXE Comparison

LPTX vs KLXE Comparison

Compare LPTX & KLXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • KLXE
  • Stock Information
  • Founded
  • LPTX 2011
  • KLXE 2018
  • Country
  • LPTX United States
  • KLXE United States
  • Employees
  • LPTX N/A
  • KLXE N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • KLXE Oilfield Services/Equipment
  • Sector
  • LPTX Health Care
  • KLXE Energy
  • Exchange
  • LPTX Nasdaq
  • KLXE Nasdaq
  • Market Cap
  • LPTX 11.1M
  • KLXE 35.8M
  • IPO Year
  • LPTX N/A
  • KLXE N/A
  • Fundamental
  • Price
  • LPTX $0.32
  • KLXE $1.84
  • Analyst Decision
  • LPTX Hold
  • KLXE
  • Analyst Count
  • LPTX 1
  • KLXE 0
  • Target Price
  • LPTX N/A
  • KLXE N/A
  • AVG Volume (30 Days)
  • LPTX 749.3K
  • KLXE 86.5K
  • Earning Date
  • LPTX 11-12-2025
  • KLXE 10-30-2025
  • Dividend Yield
  • LPTX N/A
  • KLXE N/A
  • EPS Growth
  • LPTX N/A
  • KLXE N/A
  • EPS
  • LPTX N/A
  • KLXE N/A
  • Revenue
  • LPTX N/A
  • KLXE $667,400,000.00
  • Revenue This Year
  • LPTX N/A
  • KLXE N/A
  • Revenue Next Year
  • LPTX N/A
  • KLXE $3.97
  • P/E Ratio
  • LPTX N/A
  • KLXE N/A
  • Revenue Growth
  • LPTX N/A
  • KLXE N/A
  • 52 Week Low
  • LPTX $0.22
  • KLXE $1.46
  • 52 Week High
  • LPTX $4.79
  • KLXE $7.40
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 57.28
  • KLXE 48.29
  • Support Level
  • LPTX $0.28
  • KLXE $1.77
  • Resistance Level
  • LPTX $0.29
  • KLXE $1.94
  • Average True Range (ATR)
  • LPTX 0.02
  • KLXE 0.13
  • MACD
  • LPTX 0.00
  • KLXE -0.01
  • Stochastic Oscillator
  • LPTX 98.75
  • KLXE 26.19

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

About KLXE KLX Energy Services Holdings Inc.

KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.

Share on Social Networks: